Wang Tongfei, Li Wei, Li Haitao, Li Weina
Department of Oncology, Xi'an No. 3 Hospital, the Affiliated Hospital of Northwest University, Xi'an, Shaanxi 710018, China.
Department of Orthopedics, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, China.
Saudi J Biol Sci. 2021 Mar;28(3):1561-1568. doi: 10.1016/j.sjbs.2021.01.013. Epub 2021 Jan 20.
Non-small cell lung cancer (NSCLC) is the main reason of cancer linked mortality and around 80% of cases diagnosed in advanced stage. Therefore current study designed to evaluate the deregulation of miRNA-194 and miRNA-192 in different body fluid of Non small cell lung cancer participants. Present study recruited newly diagnosed histopathologically confirmed. It was observed that the 40% NSCLC participants showed elevated miR-194 expression and 60% NSCLC participants showed reduced miR-194 expression in serum sample while in Bronchial wash, only 20% NSCLC participants showed elevated miR-194 expression while 80% showed reduced miR-194 expression (p = 0.003). It was found that the 54% NSCLC participants showed elevated miR-192 expression and 55% NSCLC participants showed reduced miR-192 expression in serum sample while In Bronchial wash sample, only 25% NSCLC participants showed high miR-192 expression while 75% showed low miR-192 expression (P = 0.0004). Expression of miR-194 was significantly associated with TNM stages (p < 0.0001, p < 0.0001), distant organ metastases (p < 0.0001, p < 0.0001), pathological grade (p = 0.0009, p = 0.0005) among serum sample and bronchial wash sample. Same observation was found with expression of miR-192 and it was significantly associated with TNM stages (p < 0.0001, p < 0.0001), distant organ metastases (p < 0.0001, p < 0.0001), pathological grade (p = 0.006, p = 0.001) among serum sample and bronchial wash sample. It was observed that the NSCLC participants who had high serum based miR-194 expression showed 22 months of overall median survival while low expression of serum based miR-194 expression showed 18 months of overall median survival. Present study suggests that decreased expression of miR-194 and miR-192 was significantly associated with different clinical features of NSCLC cases. However, significantly higher number of NSCLC cases showed low expression of miR-194 and miR-192 in bronchial lavage sample. Decreased poor overall survival was found to be associated with bronchial wash sample with respect to low miR-194 and miR-192 expression while NSCLC participants showed better overall survival with high miR-194 and miR-192 expression. This suggested decreased expression of miR-192 and miR-194 expression could be the potential prognostic marker among NSCLC participants.
非小细胞肺癌（NSCLC）是癌症相关死亡的主要原因，约80%的病例在晚期被诊断出来。因此，当前研究旨在评估非小细胞肺癌患者不同体液中miRNA - 194和miRNA - 192的失调情况。本研究招募了新诊断的经组织病理学确诊的患者。观察发现，40%的非小细胞肺癌患者血清样本中miR - 194表达升高，60%的非小细胞肺癌患者血清样本中miR - 194表达降低；而在支气管灌洗样本中，只有20%的非小细胞肺癌患者miR - 194表达升高，80%的患者miR - 194表达降低（p = 0.003）。研究发现，54%的非小细胞肺癌患者血清样本中miR - 192表达升高，55%的非小细胞肺癌患者血清样本中miR - 192表达降低；而在支气管灌洗样本中，只有25%的非小细胞肺癌患者miR - 192表达升高，75%的患者miR - 192表达降低（P = 0.0004）。血清样本和支气管灌洗样本中miR - 194的表达与TNM分期（p < 0.0001，p < 0.0001）、远处器官转移（p < 0.0001，p < 0.0001）、病理分级（p = 0.0009, p = 0.0005）显著相关。miR - 192的表达也有相同的观察结果，它与血清样本和支气管灌洗样本中的TNM分期（p < 0.0001，p < 0.0001）、远处器官转移（p < 0.0001，p < 0.0001）、病理分级（p = 0.006, p = 0.001）显著相关。观察到血清中miR - 194表达高的非小细胞肺癌患者总中位生存期为22个月，而血清中miR - 194表达低的患者总中位生存期为18个月。本研究表明miR - 194和miR - 192表达降低与非小细胞肺癌病例的不同临床特征显著相关。然而在支气管灌洗样本中，显著更多的非小细胞肺癌病例显示miR - 194和miR - 192表达低。相对于miR - 194和miR - 192低表达，支气管灌洗样本中不良总生存期降低；而非小细胞肺癌患者miR - 194和miR - 192高表达时总生存期更好。这表明miR - 192和miR - 194表达降低可能是非小细胞肺癌患者潜在的预后标志物。
